Trial Profile
Investigation of the effect of empagliflozin on cardiac sympathetic and parasympathetic nerve activity in Japanese patients with type 2 diabetes
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2020
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms EMPYREAN study
- 21 Oct 2020 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2017 New trial record